About
MDxHealth SA develops molecular diagnostic tests using proprietary genetic and epigenetic technologies to aid in the diagnosis, prognosis, and treatment decision-making of prostate cancer and other urologic cancers.
Explore MDxHealth SA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.